Ceragenix Pharmaceuticals, Inc. ("Ceragenix" or the "Company"), a development stage biopharmaceutical company, today announced that it has entered into a Cooperative Research and Development Agreement ("CRADA") with the Centers for Disease Control and Prevention ("CDC") to evaluate the efficacy of Ceragenix's Ceracide(TM) antimicrobial coating for the prevention of bacterial biofilm growth on medical devices. The Company had previously announced entering into a letter of intent with the CDC on this project.
